MedTrace Logo

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

NCT04970940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-07-21

No results posted yet for this study

Summary

To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

Treatment A

AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days

DRUG

Treatment B

AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days

DRUG

Treatment C

AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days

Sponsors & Collaborators

  • AJU Pharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min-gul Kim · Jeonbuk University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-02
Primary Completion
2020-10-07
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970940 on ClinicalTrials.gov